Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference
Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference
WALTHAM, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Justin Renz, Chief Financial and Operations Officer, and Eric Foster, Chief Commercial Officer, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 at 12:30pm EST in New York City.
馬薩諸塞州沃爾瑟姆，2024年11月20日（環球新聞）——ardelyx公司（納斯達克：ARDX），一家致力於發現、開發和商業化滿足重大未滿足醫療需求的創新首創藥物的生物製藥公司，今天宣佈，首席財務和運營官Justin Renz以及首席商務官Eric Foster將於2024年12月4日東部時間12:30在紐約市參加派傑投資第36屆年度醫療會議的圓桌討論。
To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at . A replay of the panel presentation will be available on the Ardelyx website for 30 days following the event.
要觀看小組演示的直播網絡視頻，請訪問ardelyx網站上的活動和演示頁面。 活動結束後的30天內，在ardelyx網站上可回放小組演示。
About Ardelyx, Inc.
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA (tenapanor) and XPHOZAH (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
關於Ardelyx醫療公司
Ardelyx致力於發現、開發並商業化創新的、首創的藥物，以滿足重大未滿足的醫療需求。Ardelyx在美國有兩個商業化產品獲得批准，即IBSRELA（tenapanor）和XPHOZAH（tenapanor）。Ardelyx已經達成在美國以外地區開發和商業化tenapanor的協議。Kyowa Kirin在日本商業化PHOZEVEL（tenapanor）用於治療高磷血癥。Fosun Pharma已經提交了治療高磷血癥tenapanor的新藥申請。Knight Therapeutics在加拿大商業化IBSRELA。欲了解更多信息，請訪問公司的網站，並添加我們的X (曾用名Twitter)、LinkedIn和Facebook聯繫我們。
Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com
投資者和媒體聯繫人：
Caitlin Lowie
clowie@ardelyx.com
譯文內容由第三人軟體翻譯。
